ProfileGDS5678 / 1451189_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 20% 19% 20% 30% 20% 19% 18% 20% 21% 20% 34% 21% 20% 19% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.4991320
GSM967853U87-EV human glioblastoma xenograft - Control 22.4601819
GSM967854U87-EV human glioblastoma xenograft - Control 32.484220
GSM967855U87-EV human glioblastoma xenograft - Control 42.6359730
GSM967856U87-EV human glioblastoma xenograft - Control 52.4374420
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.5103319
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.4763318
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.456320
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.4645421
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.4579620
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7615734
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.4618721
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.4707420
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.4483619